Fig. 1: Consort diagram depicting an overview of the number of patients and plasma samples included in the PLAGAST study. | Nature Communications

Fig. 1: Consort diagram depicting an overview of the number of patients and plasma samples included in the PLAGAST study.

From: Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study

Fig. 1

ctDNA detection rates at various time points for the evaluable patient population (N = 62) are also shown. ACT adjuvant chemotherapy, ctDNA circulating tumor DNA, G/GEJ gastric/gastroesophageal junction, MRD molecular residual disease, NAT neoadjuvant therapy, QC quality control, WES whole-exome sequencing.

Back to article page